Granzyme B in Autoimmune Skin Disease

The review discussed the role of Granzyme B (GzmB) in autoimmune skin diseases, emphasizing its potential as a therapeutic target due to its elevated levels in conditions like alopecia areata, pemphigoid disease, psoriasis, systemic sclerosis, and vitiligo. GzmB contributed to skin inflammation, apoptosis, and structural protein disruption, playing a causal role in pemphigoid disease and holding diagnostic and prognostic significance in cutaneous lupus erythematosus, vitiligo, and alopecia areata. The study suggested that targeting GzmB could offer a novel treatment approach, as current therapies like corticosteroids have significant adverse effects. However, while GzmB was implicated in alopecia areata pathogenesis, a causal relationship had not been fully established. Further research was needed to explore GzmB inhibition as a treatment and to develop diagnostic tools, as its roles in autoimmune pathologies were not fully understood.